Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

  • IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics
  • Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors

Evox Therapeutics Ltd, a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual property rights therein, as well as secured exclusive access to certain engineering and manufacturing rights associated with it. This technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralizing antibodies.

“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,” said Per Lundin, Ph.D., Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”.

SourceGlobeNewsWire

Leave a Reply

Your email address will not be published. Required fields are marked *

*